Genomic Sequencing Identifies Pediatric Therapy-Related Myeloid Neoplasm Defining Variants Prior to Clinical Presentation
April 5th 2021
Somatic KMT2A rearrangements, RAS/MAPK mutations, RUNX1 and TP53 alterations, and MECOM overexpression were all found to be common oncogenic drivers of pediatric therapy-related myeloid neoplasms, arising predominantly after exposure to cytotoxic therapy and identifiable at least 1 year prior to morphologic evidence of neoplasm.